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Dua and colleagues present a timely paper describing a novel approach tooesophageal reconstruction with a surprising result. The subject is a man whorequired anterior spinal plating following a car accident. Some years’ later, theplates became infected, and this resulted in a large upper oesophageal andpharyngeal defect. Whilst it was possible to treat the infection and repair some ofthe pharynx, the remaining oesophageal defect made eating impossible and(potentially fatal) mediastinitis likely. The authors fashioned a repair composedof an expandable stent wrapped in a commercial extra-cellular matrixpreparation (AlloDerm®, LifeCell Corporation, NJ) and coated with platelet-richplasma gel. The stent was removed at two years, and four years’ later theunderlying oesophageal tissue appeared to have regenerated in all its layers, asmeasured by ultrasound. Oesophageal manometry and impedence wasapproaching normal in the repaired zone when swallowing liquids and at thetime of reporting he was maintaining his weight through oral feeding alone1.
2A key to understanding the contribution of the implanted graft material, and aninteresting approach, lies in the endoscopic ultrasound data. This appears toconfirm complete regeneration of all layers of the oesophagus using a cell-freeengineered construct, which is remarkable given the presumed complexity ofthis organ. Previous authors have used AlloDerm® to repair muscle defects incongenital diaphragmatic hernia with very high recurrence rate2. Based on theultrasonic images presented here, it is not possible to completely exclude thatthe engineered construct may have led to a fibrotic residuum, rather than anormal 5-layer wall throughout. The ultrasound data is not presented at multiplelevels and this limits the conclusions somewhat, as readers may have liked toassess the appearance of the whole oesophagus and not just that segmentassumed to the ‘regenerated’ section. However, if the images are trulyrepresentative and backed in larger numbers by physiological data, then atechnically straightforward, though protracted, new tissue-engineeringtreatment could become available.
The ethics of compassionate use implantation of tissue-engineered organs hascome under intense, but necessary scrutiny3. Proponents argue that the early useof new technologies in patients, where those patients have no suitableconventional treatment, provides safety and potential efficacy data for formalclinical trials in a far more relevant way than that delivered by animal andbench-top (e.g. ‘organotypic’) models4; that results from ‘one successful human(as here) is worth more than that of ten thousand mice’. However, such seriouslyill patients are generally not ‘typical’, with highly disordered physiology and, inthe case of surgical disorders, anatomy. Thus, sceptics argue that you cannot
3understand the underlying mechanisms for success or failure in such patients,and that well-designed animal studies are the most appropriate precedents toearly phase clinical trials3.
Schwartz described three categories of surgical innovation: practice variation(minor changes to technique covered by routine consent forms), experimentalresearch (formal trials), but also a Transition Zone in between these twopositions5. She outlines the ETHICAL (Expertise, Technical skill, Hazardawareness, Informed consent, Conflict of interest avoidance, Analysis of results,Literature publication) model for the appropriate conduct of such studies, whichseeks to protect both patient and surgeon, as well as maximise learning, andscientific hypothesis generation, from the experience.
The present case falls into this Transition Zone. The authors used localcompassionate use guidance to apply technology that might otherwise havetaken years to go through formal, and funded, clinical trials4. Both the FDA andthe local IRB appear to have been consulted and content for the implant to goahead, and dedicated consent was obtained. The surgeons were technicallyexpert and had no obvious conflict of interest. Importantly, they have analysedtheir results and published them.
Despite this success, however, testing in preclinical models remains essential,although individual components of the technology are reflected in other groups’experiments as reviewed in the paper’s discussion section (References 13, 19,49, 531). Both ECM and platelet-rich plasma have regenerative potentials that are
4related to their angiogenic5 and immunomodulatory6 properties. Reversetranslation should drive this group and others to test the hypothesis generatedby this clinical success. If an accelerated treatment process, backed by well-designed animal studies and based on the learning points herein, successfullyreplicates the observations reported in this paper in formal phase 1/2 clinicaltrials, then the method could have a significant impact on oesophageal surgeryfor both benign and malignant conditions.
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